secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001367644-25-000188
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M
------------------------------------------------------------------------------

- Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.
- Total 2025 projected sales for ACAM2000 and ancillary products exceed $120M from diverse customer base.
- ACAM2000 is FDA-approved for smallpox (2007) and mpox (Aug 2024); also licensed in Canada, Australia, Singapore.
- Modification exercises Option Year 6 under existing 10-year ASPR contract (75A50119C00071).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/0001367644-25-000188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/ebs-20250905.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer